Navigation Links
Trovagene Launches Urine-Based HPV Test
Date:3/27/2013

heir healthcare providers. Physicians interested in utilizing the Trovagene assay should contact Client Services at 888-391-7992. For more information, please visit www.trovagene.com/HPV

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.  Trovagene is leveraging its intellectual property in oncogene mutations via out-licensing and use of its transrenal technologies to extend oncogene mutation detection using urine as a sample.  As a non-invasive and abundant sample, urine may overcome many of the cost and collection challenges associated with biopsy, as well as the volume limitations of blood.

Trovagene has a strong patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myelogenous leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in chronic lymphocytic leukemia (CLL) patients, as well as other hematologic malignancies.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that coul
'/>"/>

SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Trovagene Appoints Mark Erlander, Ph.D. as Chief Scientific Officer
2. Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
3. Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
4. Trovagene and Barretos Cancer Hospital, Brazil, to Evaluate Urine-Based HPV Assay as Potential Pap Smear Replacement
5. Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
6. Dr. Paul Billings joins Trovagenes Scientific Advisory Board
7. Trovagene, Inc., Announces Third Quarter and Year to Date Earnings, Provides Milestone Update
8. Trovagene and Strand Life Sciences Agree to Validate and Commercialize Urine-Based HPV Test in India and South Asia
9. Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
10. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
11. Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... N.C. , Aug. 27, 2014 Kewaunee ... its Board of Directors increased its quarterly cash dividend ... eleven cents per outstanding share, beginning with the dividend ... at the close of business on September 8, 2014. ... Founded in 1906, Kewaunee Scientific Corporation is a ...
(Date:8/27/2014)... 2014 Amgen (NASDAQ: AMGN ) ... has granted priority review designation for ivabradine for the ... oral drug that inhibits the I f ... body,s cardiac pacemaker. 1 Ivabradine works to slow ... or ventricular repolarization. 1 Heart failure is a ...
(Date:8/27/2014)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), ... for its third quarter of fiscal 2014: For ... Revenue of $1,291,378, a 13% decrease over the same period ... quarter of $240,156 compared to net income of $238,826 during ... For the nine months ended June 30, 2014: ...
Breaking Medicine Technology:FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 2FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 4FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 5FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 6FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 7Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3
(Date:8/27/2014)... of hormone therapy has spawned a prevalent but preventable ... hot flashes, according to a study by a Yale ... the study published in the Aug. 27 online issue ... that moderate to severe hot flashes also called ... women. Women with VMS experience more than feeling hot; ...
(Date:8/27/2014)... (PDT, which uses topical agents and light to kill ... common skin lesion caused by sun damage) at three ... to freeze lesions). , Author: Gayatri Patel, ... Center, in Sacramento, and colleagues. , Background: ... found on individuals with fair complexions who have had ...
(Date:8/27/2014)... Michigan Head & Neck Institute is hosting a school ... school by ensuring they have everything they need for a ... Michigan Head & Neck Institute wants to ensure the children ... "There are a lot of military families in the area, ... back to our community," said Lauren Taylor, Marketing Coordinator at ...
(Date:8/27/2014)... Dr. Stewart Shofner and Dr. Kevin ... suffering from impaired vision. Some of the most common ... . Recently, Dr. Shofner has noticed a significant increase ... and also online. To help patients understand the facts, ... , 1)    Myth: People with perfect vision won’t develop glaucoma. ...
(Date:8/27/2014)... Washington, New York (PRWEB) August 27, 2014 ... dedicated to protecting the rights of victims injured by ... new rules in place for discovery procedures, specifically Collection ... brought over C.R. Bard’s transvaginal mesh devices. (MDL No. ... Products Liability Litigation, the United States District Court, Southern ...
Breaking Medicine News(10 mins):Health News:The high cost of hot flashes: Millions in lost wages preventable 2Health News:Photodynamic therapy vs. cryotherapy for actinic keratoses 2Health News:Michigan Head & Neck Institute is Conducting Their 2nd Annual School Supplies Drive at Their Facility to Benefit Local Year-Round Elementary School Students 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 4Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 2Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 3Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 4
... Catalyst,Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today ... Third Quarter 2007 Results For the quarter ... of $734,347 or $0.06 loss per basic and diluted ... loss per basic and diluted share for the,same period ...
... Nov. 14 (HealthDay News) -- A protein that may have ... be a biomarker that indicates severe asthma. And it may ... to new research. , Reporting in the Nov. 15 issue ... University researchers said that people with severe asthma were more ...
... aim . . . , As the ... a high performance bullet based on technology developed at ... precision and superior terminal ballistics and is lead-free and ... Wakeman, Ohio, the technology is first being made available ...
... Reason for their added survival remains unclear, scientists say ... Hispanics appear to live longer following an Alzheimer,s diagnosis ... men and women of Asian and American Indian descent ... expectancies equivalent to that of white Alzheimer,s patients, ...
... December 31, RICHARDSON, Texas, Nov. 14 Blue ... will offer three Medicare Part D,prescription drug plans with ... Medicare beneficiaries in Texas can sign up,for or switch ... open enrollment period, which begins November 15 and continues ...
... Inc. announced today that CC Detect(SM), the ... now available from Panacea,Laboratories. CC Detect(SM) is ... identification of individuals with cancer of the ... standard screening methods. Panacea Laboratories,a division of ...
Cached Medicine News:Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 2Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 3Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 4Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 5Health News:Defensive Protein Linked to Asthma 2Health News:Defensive Protein Linked to Asthma 3Health News:Story tips from the Department of Energy's Oak Ridge National Laboratory, Nov. 2007 2Health News:Blacks, Hispanics Live Longer With Alzheimer's 2Health News:Blacks, Hispanics Live Longer With Alzheimer's 3Health News:Blacks, Hispanics Live Longer With Alzheimer's 4Health News:Blue Cross and Blue Shield of Texas Announces Flexible, Affordable Blue MedicareRx(SM) Medicare Prescription Drug Plans 2Health News:Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer 2Health News:Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer 3Health News:Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer 4Health News:Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer 5
... Expandable, Multichannel Pipettor The Equalizer ... productivity with an industry breakthroughequal tip spacings ... a slide rod. This innovation allows the ... vessels with different configurations. Adjustable and ...
... Ergonomic Design for Unparalleled Comfort Pick ... Notice the balance. Notice the trigger and ejector ... Thats because our pipettors are ergonomically designed to ... hours of pipetting. Productivity In The Palm ...
... Design for Unparalleled Comfort Pick one of ... balance. Notice the trigger and ejector positionsright where ... our pipettors are ergonomically designed to help avoid ... pipetting. Productivity In The Palm Of Your ...
... Ergonomic Design for Unparalleled Comfort Pick ... Notice the balance. Notice the trigger and ejector ... Thats because our pipettors are ergonomically designed to ... hours of pipetting. Productivity In The Palm ...
Medicine Products: